Our finding that SPOP mutation triggers replication catastrophe, massive DNA breaks, and cell death upon ATR inhibition highlights that prostate cancers harboring SPOP mutations may be susceptible to treatment with ATR inhibitors. Here, ATR is linked to prostate carcinoma.